Dr Rob Quinn

Interim Chief Executive Officer
Rob brings a wealth of both scientific and financial experience to Aptamer Group, with particular expertise in publicly listed biotechnology and pharmaceutical companies. From 2019-2021 he was CFO of Silence Therapeutics, an AIM-listed biotech company developing siRNA oligonucleotide technology to treat disease, where he oversaw the growth of the company from a $50m to $500m market capitalisation and a dual listing on Nasdaq. Rob was subsequently CFO at BenevolentAI until January 2022, an AI-driven drug discovery engine, where he played a key role in the company’s European reverse merger into a SPAC listed on Euronext Amsterdam. Prior to joining Aptamer Group, Rob was CFO at Pharnext, a biotech company listed on Euronext Paris. He has a PhD in Biochemistry from the University of Manchester, and is an Associate of The Institute of Chartered Accountants in England and Wales.